Search

for
Search:

GlossaryRitlecitinib

investigational drug targeting enzymes involved in autoimmune hair loss

Ritlecitinib is an investigational drug that targets specific enzymes known as Janus kinases (JAKs) and TEC family kinases, which are involved in the immune response. It is being studied for its potential to treat autoimmune conditions like alopecia areata, where the immune system mistakenly attacks hair follicles, leading to hair loss.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 148 results

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations, March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations, December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial

20 citations, December 2021 in “Journal of the American Academy of Dermatology”

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

6 citations, November 2023 in “Clinical Pharmacokinetics”

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study

research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study

July 2025 in “The Journal of Dermatology”

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

View more "ritlecitinib" in research →

Community Join

4 / 4 results

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 5 upvotes 1 year ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community Article of all potential future cures

in Treatment 25 upvotes 4 months ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials

in Research/Science 263 upvotes 1 month ago

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

community How do we only have two treatments to combat hair loss at this point in time?

in Chat 211 upvotes 2 years ago

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.